Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
Eisai Sees Subcutaneous Autoinjector as Key to Boosting US Demand for Leqembi
Eisai Executive Vice President and COO Keisuke Naito expects that the approval-pending subcutaneous autoinjector (SC-AI) version of Leqembi (lecanemab) will serve as a key engine for driving demand for the Alzheimer’s drug in the US. Speaking at the company’s earnings…
To read the full story
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





